Skip to contentpdufa.bio
Home › Decisions › JNJ 2026-11-05

RYBREVANT FASPRO FDA approval for head and neck cancer: Nov 5, 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET
✓ APPROVED

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) was approved by the FDA on November 5, 2026 for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody (accelerated approval).

Verified against: FDA action day November 5, 2026 (BLA 761433 SUPPL-2 (FDA letter)) · Goal date: none on record.

This page was first committed to pdufa.bio's public repository on Nov 20, 2026, 4:09 AM ET (public commit 2b423a8). Dates on this page are the FDA's and the sponsor's; this line is ours.

Run-up into the decision (T-120 → T+5)

FDA decision 11/5/26$278.43$222.895/15/26FDA decision 11/5/26$278.43$222.895/15/26
Daily close, T-120 (5/15/26) through T+5. Run-up high $278.43 on 9/3/26, low $222.89 on 6/2/26 (T-120 to T-1). FDA decision 11/5/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-11-05
OutcomeApproved
Drug / candidateRYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj)
IndicationAdults with recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody (accelerated approval)
CompanyJohnson & Johnson
Market-cap tierLarge
120-day run-up (T-120→T-1)+19.7%
Decision-day move-1.4%
Move measured on2026-11-05 close, against the 2026-11-04 close
Cohort decision-day move (history)1.0% median (n=647)

The FDA's accelerated approval letter for BLA 761433 supplement 2, signed November 5, 2026 (FDA letter), covers RYBREVANT FASPRO as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The letter states that it is not indicated for HPV-associated oropharyngeal squamous cell carcinoma, and that the supplemental application was received on May 20, 2026. Johnson & Johnson announced the approval the same evening and reported a 42 percent overall response rate (95 percent confidence interval, 32 to 52 percent) (Johnson & Johnson, November 5, 2026). We hold no publicly disclosed PDUFA goal date for this supplement, so no early or late margin is given.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: FDA approval letter, BLA 761433 S-002

FDA record of the action: the FDA approved on November 5, 2026, per BLA 761433 SUPPL-2 (FDA letter). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Questions

Was RYBREVANT FASPRO approved for head and neck cancer?

Yes. The FDA granted accelerated approval on November 5, 2026, per its own approval letter, for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. It is not indicated for HPV-associated oropharyngeal squamous cell carcinoma.

Which company is behind RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj)?

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is a Johnson & Johnson (JNJ) program. The FDA decision came on November 5, 2026; the FDA's own record of the decision is linked on this page.

How did JNJ stock react to the FDA decision?

JNJ moved -1.4%, measured as the 2026-11-05 close against the 2026-11-04 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.